Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

Ignace Vergote, Teresa Macarulla, Fred R. Hirsch, Carsten Hagemann, David Scott Miller

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated with systemic toxicity. Multimodal treatment combinations can help improve patient outcomes; however, implementation is limited by additive toxicities and potential drug–drug interactions. As such, there is a high unmet need to develop additional therapies to enhance the efficacy of SOC treatments without increasing toxicity. Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. The therapy is locoregional and is delivered noninvasively to the tumor site via a portable medical device that consists of field generator and arrays that are placed on the patient’s skin. As a noninvasive treatment modality, TTFields therapy-related adverse events mainly consist of localized skin reactions, which are manageable with effective acute and prophylactic treatments. TTFields selectively target cancer cells through a multi-mechanistic approach without affecting healthy cells and tissues. Therefore, the application of TTFields therapy concomitant with other cancer treatments may lead to enhanced efficacy, with low risk of further systemic toxicity. In this review, we explore TTFields therapy concomitant with taxanes in both preclinical and clinical settings. The summarized data suggest that TTFields therapy concomitant with taxanes may be beneficial in the treatment of certain cancers.

Original languageEnglish
Article number636
Issue number3
StatePublished - Feb 2023


  • Tumor Treating Fields (TTFields)
  • mechanism of action
  • non-small cell lung cancer (NSCLC)
  • ovarian cancer
  • pancreatic cancer
  • taxanes


Dive into the research topics of 'Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment'. Together they form a unique fingerprint.

Cite this